NEW YORK, NY / ACCESSWIRE / December 7, 2023 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Myriad Genetics, Inc. (NASDAQ: MYGN). The settlement provides for a fund of $77,500,000 to benefit class members. For the purposes of the settlement, the class is defined as: all persons who purchased or acquired Myriad common stock from August 9, 2017 until February 6, 2020, inclusive.

If you are a class member as defined above, you may be entitled to a pro-rata share of the settlement fund. In order to receive a share of the settlement, you must file a claim form by January 16, 2024.

For more details on the settlement, including a copy of the claim form, please visit: https://zlk.com/settlement-form/?redirect=aHR0cHM6Ly96bGsuY29tL3NldHRsZW1lbnQvbXlyaWFkLWdlbmV0aWNzLWluYy1zZXR0bGVtZW50&prid=51&wire=1&ticker=MYGN

Levi & Korsinsky did not act as lead counsel or otherwise participate in litigating the above class action. We are providing this information as a courtesy to remind class members of the claims deadline so they can file their forms in a timely fashion.

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP